A class of multi-branched drug conjugates capable of specifically targeting CD44 are disclosed. This class of compounds binds specifically to CD44 and can target tumor cells and tissues with high CD44 expression, thereby resulting in a high concentration of the conjugate in the target tissue, improving its clinical therapeutic effect, and reducing toxicity. decreases. The compounds of the present invention include, but are not limited to, gastric cancer, pancreatic cancer, small cell lung cancer, colon cancer, breast cancer, lung adenocarcinoma, liver cancer, nasopharyngeal carcinoma, malignant glioma, lymphoma, renal carcinoma, ovarian cancer, head and neck cancer, squamous cell carcinoma, and the like. It is suitable for treating all tumors with high CD44 expression.
展开▼
